Who pays in the Humira patent settlement? Patients, of course.

Investors win, but patients lose as AbbVie protects the world's best-selling drug, Humira, from generic competition for another six years.

from nicholemhearn digest http://www.chicagobusiness.com/article/20171004/BLOGS10/171009957/who-pays-in-the-humira-patent-settlement-patients-of-course?utm_source=BLOGS10&utm_medium=rss&utm_campaign=chicagobusiness